AIM ImmunoTech Inc. has released a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, who discusses results from a Phase 2 study on Ampligen® for treating Post-COVID fatigue.
Company Information
Company
AIM ImmunoTech
Location
Ocala, Florida, United States
About
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
Fundz sees it the moment AIM ImmunoTech ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical